株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血友病A:パイプライン分析

Hemophilia A - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232826
出版日 ページ情報 英文 159 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.29円で換算しております。
Back to Top
血友病A:パイプライン分析 Hemophilia A - Pipeline Review, H2 2016
出版日: 2016年11月23日 ページ情報: 英文 159 Pages
概要

血友病 A はX染色体連鎖劣性欠損症で、血液の凝固第VIII因子(FVIII)の不足によって引き起こされ、遺伝あるいは自然突然変異によって発症します。 FVIII活動のレベルに応じて、血友病患者は、あざができやすかったり、外傷を受けても十分に凝固しなかったりし、重度の血友病では自発性出血を伴います。 症状は、痛みと腫れを伴う関節内出血や血尿・血便、あざ、消化管と尿路からの出血、鼻血、切り傷や抜歯、手術の際の長引く出血、突発性出血などが挙げられます。

当レポートでは、血友病Aの治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

血友病 A 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics B.V.
  • Apitope International NV
  • Baxalta Incorporated
  • Bayer AG
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • Catalyst Biosciences, Inc.
  • CSL Limited
  • DBV Technologies S.A.
  • Dimension Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • EpiVax, Inc.
  • Expression Therapeutics LLC
  • F. Hoffmann-La Roche Ltd.
  • Green Cross Corporation
  • Idogen AB
  • Lentigen Technology, Inc.
  • mAbxience S.A.
  • Novo Nordisk A/S
  • Octapharma AG
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Pharming Group N.V.
  • rEVO Biologics, Inc.
  • Sangamo BioSciences, Inc.
  • SK Chemicals Co., Ltd.
  • Spark Therapeutics, Inc.
  • The International Biotechnology Center (IBC) Generium
  • UniQure N.V.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8692IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H2 2016, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 8, 4, 4, 21, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.Hemophilia A.

Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hemophilia A Overview
  • Therapeutics Development
    • Pipeline Products for Hemophilia A - Overview
    • Pipeline Products for Hemophilia A - Comparative Analysis
  • Hemophilia A - Therapeutics under Development by Companies
  • Hemophilia A - Therapeutics under Investigation by Universities/Institutes
  • Hemophilia A - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Hemophilia A - Products under Development by Companies
  • Hemophilia A - Products under Investigation by Universities/Institutes
  • Hemophilia A - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals Inc
    • Amarna Therapeutics BV
    • Apitope International NV
    • Bayer AG
    • Biogen Inc
    • BioMarin Pharmaceutical Inc
    • Catalyst Biosciences Inc
    • Chugai Pharmaceutical Co Ltd
    • CSL Ltd
    • DBV Technologies SA
    • Dimension Therapeutics Inc
    • Emergent BioSolutions Inc
    • EpiVax Inc
    • Expression Therapeutics LLC
    • Green Cross Corp
    • Idogen AB
    • Lentigen Technology Inc
    • mAbxience SA
    • Novo Nordisk A/S
    • Octapharma AG
    • OPKO Biologics Ltd
    • Pfizer Inc
    • Pharming Group NV
    • rEVO Biologics Inc
    • Sangamo BioSciences Inc
    • Shire Plc
    • SK Chemicals Co Ltd
    • Spark Therapeutics Inc
    • UniQure NV
    • XL-protein GmbH
  • Hemophilia A - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • antihemophilic factor - Drug Profile
    • antihemophilic factor (human) - Drug Profile
    • antihemophilic factor (recombinant) - Drug Profile
    • antihemophilic factor (recombinant) - Drug Profile
    • antihemophilic factor (recombinant) - Drug Profile
    • antihemophilic factor (recombinant) - Drug Profile
    • antihemophilic factor (recombinant) - Drug Profile
    • antihemophilic factor (recombinant) - Drug Profile
    • antihemophilic factor (recombinant) biosimilar - Drug Profile
    • antihemophilic factor (recombinant) biosimilar - Drug Profile
    • antihemophilic factor (recombinant), pegylated - Drug Profile
    • antihemophilic factor (recombinant), single chain - Drug Profile
    • ATXF-8117 - Drug Profile
    • BAX-888 - Drug Profile
    • BAY-1093884 - Drug Profile
    • BMN-270 - Drug Profile
    • Cell Therapy to Target Coagulation Factor VIII for Hemophilia A - Drug Profile
    • coagulation factor VIIa (recombinant) - Drug Profile
    • coagulation factor VIII (human) - Drug Profile
    • concizumab - Drug Profile
    • CSL-689 - Drug Profile
    • damoctocog alfa pegol - Drug Profile
    • Deimmunized FVIII - Drug Profile
    • DTX-201 - Drug Profile
    • emicizumab - Drug Profile
    • ET-3 - Drug Profile
    • fitusiran - Drug Profile
    • Gene Therapy for Hematological Disorders - Drug Profile
    • Gene Therapy for Hemophilia A - Drug Profile
    • Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile
    • IN-3012 - Drug Profile
    • Kovaltry - Drug Profile
    • LG-889 - Drug Profile
    • LR-769 - Drug Profile
    • marzeptacog alfa - Drug Profile
    • MG-1113A - Drug Profile
    • MOD-5014 - Drug Profile
    • PBB-8-IN - Drug Profile
    • PF-06741086 - Drug Profile
    • Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile
    • Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile
    • Recombinant Protein for Hemophilia A - Drug Profile
    • Recombinant Proteins for Hemophilia A - Drug Profile
    • SB-525 - Drug Profile
    • SB-FVIII - Drug Profile
    • SHP-656 - Drug Profile
    • SPK-8011 - Drug Profile
    • SVF-VIIa - Drug Profile
  • Hemophilia A - Dormant Projects
  • Hemophilia A - Discontinued Products
  • Hemophilia A - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hemophilia A, H2 2016
  • Number of Products under Development for Hemophilia A - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hemophilia A - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016
  • Hemophilia A - Pipeline by Amarna Therapeutics BV, H2 2016
  • Hemophilia A - Pipeline by Apitope International NV, H2 2016
  • Hemophilia A - Pipeline by Bayer AG, H2 2016
  • Hemophilia A - Pipeline by Biogen Inc, H2 2016
  • Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H2 2016
  • Hemophilia A - Pipeline by Catalyst Biosciences Inc, H2 2016
  • Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
  • Hemophilia A - Pipeline by CSL Ltd, H2 2016
  • Hemophilia A - Pipeline by DBV Technologies SA, H2 2016
  • Hemophilia A - Pipeline by Dimension Therapeutics Inc, H2 2016
  • Hemophilia A - Pipeline by Emergent BioSolutions Inc, H2 2016
  • Hemophilia A - Pipeline by EpiVax Inc, H2 2016
  • Hemophilia A - Pipeline by Expression Therapeutics LLC, H2 2016
  • Hemophilia A - Pipeline by Green Cross Corp, H2 2016
  • Hemophilia A - Pipeline by Idogen AB, H2 2016
  • Hemophilia A - Pipeline by Lentigen Technology Inc, H2 2016
  • Hemophilia A - Pipeline by mAbxience SA, H2 2016
  • Hemophilia A - Pipeline by Novo Nordisk A/S, H2 2016
  • Hemophilia A - Pipeline by Octapharma AG, H2 2016
  • Hemophilia A - Pipeline by OPKO Biologics Ltd, H2 2016
  • Hemophilia A - Pipeline by Pfizer Inc, H2 2016
  • Hemophilia A - Pipeline by Pharming Group NV, H2 2016
  • Hemophilia A - Pipeline by rEVO Biologics Inc, H2 2016
  • Hemophilia A - Pipeline by Sangamo BioSciences Inc, H2 2016
  • Hemophilia A - Pipeline by Shire Plc, H2 2016
  • Hemophilia A - Pipeline by SK Chemicals Co Ltd, H2 2016
  • Hemophilia A - Pipeline by Spark Therapeutics Inc, H2 2016
  • Hemophilia A - Pipeline by UniQure NV, H2 2016
  • Hemophilia A - Pipeline by XL-protein GmbH, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Actions H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hemophilia A - Dormant Projects, H2 2016
  • Hemophilia A - Dormant Projects (Contd..1), H2 2016
  • Hemophilia A - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hemophilia A, H2 2016
  • Number of Products under Development for Hemophilia A - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top